Drug Profile
AMG 208
Alternative Names: AMG-208Latest Information Update: 30 Mar 2016
Price :
$50
*
At a glance
- Originator Amgen
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 14 Apr 2015 MD Anderson Cancer Center and Amgen withdraw a phase II trial in castrate-resistant prostate cancer (Metastatic disease) in USA prior to enrolment (NCT02420587)
- 01 Dec 2014 Amgen completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT00813384)
- 05 Feb 2010 Phase-I development is ongoing in USA